Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see if adding radiation therapy to standard medical treatments works better than standard therapies alone in people with kidney cancer. The standard therapies include:
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
In addition, their cancers have a mutation (change) in the G12C location of the KRAS gene. Olomorasib may help slow or stop the growth of cancers with KRAS G12C mutations. It is taken orally (by mouth).
Researchers are assessing the combination of BNT326 and BNT327 in people with advanced lung cancer that has spread. The people in this study have non-small cell lung cancer (NSCLC) that came back or keeps growing after treatment.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
